3 Reasons Why Pfizer Investors Will Win With a Consumer Business Sale or Spinoff
Nearly a year ago, reports surfaced that Pfizer (NYSE: PFE) was considering selling or spinning off its consumer healthcare business. But those were just reports. Nothing happened -- until now.
On Tuesday, Pfizer officially announced that it was "reviewing strategic alternatives" for its consumer healthcare business. Those alternatives include a sale, a spinoff, or ultimately keeping the business within Pfizer. Shareholders should be cheering for the first two options. Here are three reasons why Pfizer investors will win if the company decides to sell or spin off its consumer business.
Image source: Getty Images.
Source: Fool.com
Johnson & Johnson Stock
€138.98
0.330%
The stock is one of the favorites of our community with 57 Buy predictions and 2 Sell predictions.
With a target price of 163 € there is a slightly positive potential of 17.28% for Johnson & Johnson compared to the current price of 138.98 €.
